<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04087811</url>
  </required_header>
  <id_info>
    <org_study_id>16-VISS-01</org_study_id>
    <nct_id>NCT04087811</nct_id>
  </id_info>
  <brief_title>Postmarket Registry for Evaluation of the Superion® Spacer</brief_title>
  <acronym>PRESS</acronym>
  <official_title>Postmarket Registry for Evaluation of the Superion® Spacer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To gather evidence documenting the performance and clinical outcomes associated with
      treatment of moderate degenerative lumbar spinal stenosis using the Superion® Indirect
      Decompression System (IDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To gather evidence documenting the performance and clinical outcomes associated with
      treatment of moderate degenerative lumbar spinal stenosis using the Superion® IDS in patients
      ≥45 years of age suffering from symptoms of neurogenic intermittent claudication secondary to
      a confirmed diagnosis of moderate degenerative lumbar spinal stenosis at one or two
      contiguous levels from L1 to L5.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 28, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Vertiflex® Patient Satisfaction Survey</measure>
    <time_frame>3 Week Follow-Up Visit</time_frame>
    <description>A score of ≥3 in each questionnaire component will be deemed a clinically meaningful outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vertiflex® Patient Satisfaction Survey</measure>
    <time_frame>6 Month Follow-Up Visit</time_frame>
    <description>A score of ≥3 in each questionnaire component will be deemed a clinically meaningful outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vertiflex® Patient Satisfaction Survey</measure>
    <time_frame>12 Month Follow-Up Visit</time_frame>
    <description>A score of ≥3 in each questionnaire component will be deemed a clinically meaningful outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale (VAS), Back and Leg Pain</measure>
    <time_frame>Pre-Operative Assessment, 3 Week, 6 Month and 12 Month Follow-Up Visit</time_frame>
    <description>A change of 20 mm (on a 100 mm scale) from baseline is considered a clinically meaningful outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Achievement of Self-Defined Functional Objective</measure>
    <time_frame>Pre-Operative Assessment, 3 Week, 6 Month and 12 Month Follow-Up Visit</time_frame>
    <description>A change of ≥3 is considered evidence of significant improvement in function</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1666</enrollment>
  <condition>Lumbar Spinal Stenosis</condition>
  <arm_group>
    <arm_group_label>Superion® Indirect Decompression System (IDS)</arm_group_label>
    <description>Superion® Indirect Decompression System (IDS) - Interspinous Spacer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Superion® Indirect Decompression System (IDS)</intervention_name>
    <description>Superion® Indirect Decompression System (IDS) (Superion® implant)</description>
    <arm_group_label>Superion® Indirect Decompression System (IDS)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from symptoms of neurogenic intermittent claudication secondary to a
        confirmed diagnosis of moderate degenerative lumbar spinal stenosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female patients ≥45 years of age

          -  symptoms of neurogenic intermittent claudication and a confirmed diagnosis of moderate
             degenerative lumbar stenosis at one or two contiguous levels from L1 to L5

          -  meeting the labeled indications for use of the Superion® Indirect Decompression System
             (IDS)

        Exclusion Criteria:

          -  not contraindicated as described in the labeled indications for use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roshini Jain</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Scientific Clinical Research</name>
      <address>
        <city>Valencia</city>
        <state>California</state>
        <zip>91355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

